Investing in tomorrow's medicine

 

Mérieux Equity Partners is a global investment platform specialized in the healthcare & nutrition sector, working alongside entrepreneurs and companies with ambitious growth plan, offering them privileged access to sector-expertise and industrial network.

News

Ivantis announces groundbreaking 3 year results from FDA clinical trial

02/05/2019

First device in Minimally Invasive Glaucoma Surgical (MIGS) category to demonstrate significant long-term reduction of severe major surgeries for glaucoma patients. This is the first study of any kind showing a MIGS device achieving a statistically significant reduction in secondary incisional surgery; over 70% of patients remain free of medications.

Mérieux Equity Partners teams up with ICG to acquire leading Italian generic company, DOC Generici

08/04/2019

DOC Generici is Italy’s largest independent generic pharmaceutical company.

Inscripta expands Series C Financing Round to $105.5 million

04/04/2019

Existing investors have agreed to contribute an additional $20 million to its previously announced Series C funding round.

Key figures

25
Supported companies
20
Team
>460
Asset Under management
(€ million)
3
Offices